Type I interferon biomarker in idiopathic inflammatory myopathies: associations of Siglec-1 with disease activity and treatment response
Authors' conclusion
Siglec-1 was increased in treatment-naive IIM patients and showed a decline after IVIG monotherapy. In DM, Siglec-1 expression correlated with relevant clinical measures.
Study context
- Population
- Newly diagnosed adult idiopathic inflammatory myopathies (IIM) patients (dermatomyositis (DM) n = 9, immune-mediated necrotizing myopathy (IMNM) n = 5, NSM/OM n = 4, antisynthetase syndrome (ASyS) n = 1) and healthy controls
- Participants
- 19 vs 9
- Comparison
- Siglec-1 expression on monocytes in newly diagnosed adult IIM patients before and after intravenous immunoglobulin (IVIG) monotherapy, and vs healthy controls
- IIMn = 19
- Healthy controlsn = 9reference
Methodological detailsexploratory analysis of a phase-2 pilot study, flow cytometry, before and after treatment
- Exploratory analysis of a phase-2 pilot study
- Flow cytometry
- Before and after treatment
Primary result
As reported in the abstract
Siglec-1 expression on monocytes
Decline in Siglec-1 expression after 9 weeks (of 15 patients with follow-up samples)
10
DM: correlation of Siglec-1 with MMT (rs)
−0.603
P = 0.013
DM: correlation of Siglec-1 with physician global activity (PhGA) (rs)
0.783
P < 0.001
DM: correlation of Siglec-1 with total improvement score (TIS) (rs)
−0.786
P = 0.036
Original publication
Type I interferon biomarker in idiopathic inflammatory myopathies: associations of Siglec-1 with disease activity and treatment response. Rheumatology (Oxford). Published 19 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →